2022 started off hot for investments in the life sciences sector. Following trends seen in 2020 and 2021, money flowed readily with investors happy to throw seven, eight and even nine figure sums at early-stage companies.
However, as the year has progressed, the economic tensions that have wrought their effects in heavy industry and consumer trade have oozed their way into health care, impacting deal size and volume
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?